130 related articles for article (PubMed ID: 11595290)
61. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
[TBL] [Abstract][Full Text] [Related]
62. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses.
Reimann KA; Parker RA; Seaman MS; Beaudry K; Beddall M; Peterson L; Williams KC; Veazey RS; Montefiori DC; Mascola JR; Nabel GJ; Letvin NL
J Virol; 2005 Jul; 79(14):8878-85. PubMed ID: 15994781
[TBL] [Abstract][Full Text] [Related]
63. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
[TBL] [Abstract][Full Text] [Related]
64. Expansion of HBV-specific memory CTL primed by dual HIV/HBV genetic immunization during SHIV primary infection in rhesus macaques.
Borgne SL; Michel ML; Camugli S; Corre B; Le Grand R; Rivière Y
Vaccine; 2001 Mar; 19(17-19):2485-95. PubMed ID: 11257382
[TBL] [Abstract][Full Text] [Related]
65. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.
Endo Y; Igarashi T; Nishimura Y; Buckler C; Buckler-White A; Plishka R; Dimitrov DS; Martin MA
J Virol; 2000 Aug; 74(15):6935-45. PubMed ID: 10888632
[TBL] [Abstract][Full Text] [Related]
66. High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum.
LaFranco-Scheuch L; Abel K; Makori N; Rothaeusler K; Miller CJ
J Virol; 2004 Jun; 78(12):6399-408. PubMed ID: 15163733
[TBL] [Abstract][Full Text] [Related]
67. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.
Voss G; Manson K; Montefiori D; Watkins DI; Heeney J; Wyand M; Cohen J; Bruck C
J Virol; 2003 Jan; 77(2):1049-58. PubMed ID: 12502820
[TBL] [Abstract][Full Text] [Related]
68. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination.
Baig J; Levy DB; McKay PF; Schmitz JE; Santra S; Subbramanian RA; Kuroda MJ; Lifton MA; Gorgone DA; Wyatt LS; Moss B; Huang Y; Chakrabarti BK; Xu L; Kong WP; Yang ZY; Mascola JR; Nabel GJ; Carville A; Lackner AA; Veazey RS; Letvin NL
J Virol; 2002 Nov; 76(22):11484-90. PubMed ID: 12388710
[TBL] [Abstract][Full Text] [Related]
69. Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone.
Stolte-Leeb N; Bieler K; Kostler J; Heeney J; Haaft PT; Suh YS; Hunsmann G; Stahl-Hennig C; Wagner R
Viral Immunol; 2008 Jun; 21(2):235-46. PubMed ID: 18476770
[TBL] [Abstract][Full Text] [Related]
70. Macaque models for AIDS vaccine development.
Johnson RP
Curr Opin Immunol; 1996 Aug; 8(4):554-60. PubMed ID: 8794019
[TBL] [Abstract][Full Text] [Related]
71. Annual updated survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.
Warren JT; Dolatshahi M
J Med Primatol; 1994; 23(2-3):184-225. PubMed ID: 7966234
[No Abstract] [Full Text] [Related]
72. Vaccines for the prevention of HIV-1 disease.
Mascola JR; Nabel GJ
Curr Opin Immunol; 2001 Aug; 13(4):489-95. PubMed ID: 11498307
[TBL] [Abstract][Full Text] [Related]
73. [Theory for prophylactic AIDS vaccine development].
Nomura T; Matano T
Uirusu; 2009 Dec; 59(2):267-75. PubMed ID: 20218335
[TBL] [Abstract][Full Text] [Related]
74. Challenges in the search for an HIV vaccine.
Lemckert AA; Goudsmit J; Barouch DH
Eur J Epidemiol; 2004; 19(6):513-6. PubMed ID: 15330122
[TBL] [Abstract][Full Text] [Related]
75. Cytotoxic T cells--protection from disease progression--protection from infection.
Gotch F; Gallimore A; McMichael A
Immunol Lett; 1996 Jun; 51(1-2):125-8. PubMed ID: 8811356
[TBL] [Abstract][Full Text] [Related]
76. Progress Towards a Therapeutic HIV DNA Vaccine.
Munson P
Expert Rev Vaccines; 2022 Jun; 21(6):783-798. PubMed ID: 35345962
[TBL] [Abstract][Full Text] [Related]
77. Toward an AIDS vaccine.
Walker BD; Burton DR
Science; 2008 May; 320(5877):760-4. PubMed ID: 18467582
[TBL] [Abstract][Full Text] [Related]
78. A model for AIDS pathogenesis.
Schenzle D
Stat Med; 1994 Oct 15-30; 13(19-20):2067-79. PubMed ID: 7846411
[TBL] [Abstract][Full Text] [Related]
79. Prospects for HIV vaccines.
Ada GL
J Acquir Immune Defic Syndr (1988); 1988; 1(3):295-303. PubMed ID: 3265153
[TBL] [Abstract][Full Text] [Related]
80. Cellular immunity and a type 1 cytokine profile in protection against HIV infection and progression to AIDS.
Clerici M; Shearer GM
Res Immunol; 1994; 145(8-9):635-41; discussion 641-3. PubMed ID: 7754213
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
